Introduction {#s1}
============

Cancer/testis (CT) genes are expressed primarily in the germ line but are also active in a number of human tumors including those of the lung, breast, ovary and skin [@pone.0012773-Simpson1]. Amongst the CT-genes is a subset with very tight transcriptional regulation that is specifically expressed in spermatogonia, completely undetectable in somatic tissues and encoded on the X-chromosome [@pone.0012773-DePlaen1]. The proteins derived from these CT-X genes are significantly immunogenic when aberrantly expressed in human tumors and are being widely studied in the context of therapeutic cancer vaccines [@pone.0012773-Caballero1], [@pone.0012773-vanderBruggen1]. Currently, two phase III trials are being undertaken with a vaccine containing the CT-X protein MAGEA3 as an adjuvant therapy for non-small cell lung cancer and melanoma [@pone.0012773-Brichard1].

Due to their strong up regulation in tumors, it has been widely speculated that the CT-X genes might play a role in the tumorigenic process. This has been difficult to prove, however, as their function remains obscure. Nevertheless a number of *in vitro* studies, focused on the MAGE proteins, have found evidence that they can interfere with p53 mediated apoptosis and promote cell proliferation [@pone.0012773-Yang1], [@pone.0012773-Monte1], [@pone.0012773-Atanackovic1], [@pone.0012773-Liu1], [@pone.0012773-Jeon1]. In addition, a number of studies have found CT-X expression to be linked with both more advanced and more aggressive tumors [@pone.0012773-Gure1], [@pone.0012773-Atanackovic2], [@pone.0012773-Bergeron1]. To complicate this scenario, however, there have also been observations that link the expression of individual MAGE genes with a better prognosis and longer survival [@pone.0012773-Grau1], [@pone.0012773-Sharma1], [@pone.0012773-Peikert1].

Recently, it has begun to be possible to undertake genome-wide investigations of somatic mutations in human tumors [@pone.0012773-Wood1], [@pone.0012773-Parsons1], [@pone.0012773-Jones1]. Within the published data, we identified reports of missense mutations in the CT-X antigen genes *MAGEA1*, *MAGEA4*, *MAGEC1*, *MAGEC2*, as well as the genes for the ubiquitously expressed *MAGEE1* (also encoded on the X chromosome) in breast and brain tumors [@pone.0012773-Wood1], [@pone.0012773-Parsons1]. Although the frequency of these mutations is low, we reasoned that their mutation might not be simply due to chance as none were observed to be mutated in colon or pancreatic tumors although the same genes were sequenced in similar numbers of tumors [@pone.0012773-Wood1], [@pone.0012773-Jones1]. Furthermore, *MAGEE1* was mutated sufficiently frequently to be classified as a candidate cancer gene (CAN-gene) in breast cancer and thus potentially a driver of tumorigenesis [@pone.0012773-Wood1].

Since greater knowledge of somatic *MAGE* mutations in human tumors might cast further light on their potential role in tumorigenesis, as well as provide important information relevant to the use of MAGE proteins in cancer vaccines, we have undertaken a systematic mutational analysis of the coding regions of the five MAGE genes in which mutations were reported (*MAGEA1, MAGEA4*, *MAGEC1*, *MAGEC2*, *MAGEE1)*. For this study we used human melanoma and ovarian samples, two tumor types with frequent CT-X expression. Our results reveal that one or more of these genes is mutated in around 35% of melanomas with some tumors exhibiting multiple mutations in these genes. On the other hand we found no mutations of these genes in ovarian tumors. Further investigations will be required to determine whether these mutations are drivers or passengers of tumorigenesis.

Materials and Methods {#s2}
=====================

Sequence analysis of the melanoma samples {#s2a}
-----------------------------------------

Tumor and matching blood samples from 27 melanoma cancer patients were collected at Lausanne University Hospital (CHUV), Switzerland. Cell lines were established from these samples at the Ludwig Institute of Cancer Research, from fresh surgery samples using mechanical or a combination of mechanical and enzymatic dissociation. All cell lines were derived from cutaneous melanomas, except for T1257A and B (mucosal melanoma). They were all from tumor metastases, except for LAU-Me300 and LAU-T1257A, which were from primary tumors. The following pairs of cell lines were established from the same patients: LAU-Me260.LN and LAU-T149D (patient 149, 7 years apart); LAU-Me275 and LAU-T50B (patient 50, 12 years apart); LAU-Me 261 and LAU-T42B (patient 42, 3 years apart); LAU-Me305 and LAU-Me317.M2 (patient 233, 6 months apart); LAU-T1257A and C (patient 1257, primary tumor and synchronous metastasis, respectively); LAU-T1262 A and B (patient 1262, synchronous metastases); LAU-T1255A/B are two independent lines from a large tumor. Established cultures were confirmed to be from human melanoma by flow cytometric analysis with antibodies against the high molecular weight melanoma- associated antigen and MHC class I molecules. Additional phenotyping was performed by flow cytometry, Western blotting and RT/PCR to assess expression of melanoma/melanocytic antigens (e.g. MART-1, tyrosinase, cancer/testis genes). Cell lines were routinely tested and found negative for mycoplasma. Cells were periodically checked for morphology and expression of selected antigens by RT/PCR.

In addition, fresh tumor and blood samples were collected from 86 patients attending the Melanoma Clinic at Austin Health, Melbourne, Australia ([Table S2](#pone.0012773.s003){ref-type="supplementary-material"}). A written informed consent was obtained from all participating subjects. This study was approved by the Ethics Committee for Clinical Research from the University of Lausanne, Switzerland, by the Human Research Ethics Committee, Research Ethics Unit, Austin Hospital, Australia and by the Ethics Committee, J. Craig Venter Institute.

Genomic DNA was extracted using a Qiagen kit following a standard protocol. Targeted sequencing was carried out with a fully automated and high-throughput production pipeline that is based on polymerase chain reaction (PCR) amplification of genomic DNA followed by traditional Sanger sequencing chemistry as previously described [@pone.0012773-Pejovic1]. Primer sequences are listed in [Table S3](#pone.0012773.s004){ref-type="supplementary-material"}. Mutational analysis was done by comparing the sequence traces between tumors and their matching blood samples. Each somatic mutation call had to be supported by both forward and reverse traces of each amplicon and was manually verified.

Cloning of and sequencing analysis of mutated *MAGEA1* in LAU-Me190 {#s2b}
-------------------------------------------------------------------

PCR was undertaken with High Fidelity Taq polymerase (Invitrogen, Carlsbad, CA) plus 10 pmol of each of the following primers in 25 µl to amplify the region containing the sequence variation in the tumor corresponding to the LAU-Me190 cell line: Forward 5′-AGAAAACCAACCAAATCAGCCA-3′and Reverse 5′-TCATGTCTCTTGAGCAGAGGAGTCT-3′. The amplification consisted of 35 cycles of a denaturation step at 94°C for 30 s, followed by 30 s at 55°C and extension at 68°C for 30 s followed by a final 7-min extension. PCR products were loaded onto 1.5% agarose gel, stained with ethidium bromide and visualized by UV illumination. The predicted size of the MAGEA1 PCR product was 340 bp. The PCR product was recovered and purified after agarose gel electrophoresis using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). Cloning in pcDNA™3.1/V5-His was performed at room temperature for 30 minutes in a total volume of 6 µl using the pcDNA™3.1/V5-His TOPO® TA Expression Kit (Invitrogen, Carlsbad, CA). Transformation was performed into chemically competent One Shot® TOP10 E. coli (Invitrogen, Carlsbad, CA) that were plated in LB plates containing 100 µg/ml ampicillin and incubated overnight at 37°C. Fifteen colonies were picked and grown overnight in LB medium containing 100 µg/ml ampicillin. Plasmids were isolated with Wizard® Plus SV Minipreps DNA Purification System (Promega Madison, WI). DNA was submitted to Sanger sequencing using the T7 promoter primer.

Results and Discussion {#s3}
======================

The entirety of *MAGEA1*, *MAGEA4* and *MAGEC2* genes and at least 70% of *MAGEC1* and *MAGEE1* could be specifically PCR amplified thus permitting detection of somatic mutations by conventional Sanger sequencing. Some regions of *MAGEC1* and *MAGEE1* could not be covered by PCR amplicons due to very high GC content or repetitive sequences.

To avoid the complication of contaminating normal tissues in fresh tumor samples, we first undertook a Discovery Screen for *MAGE* mutations using melanoma cell lines and corresponding EBV transformed leukocytes from 27 patients treated at the University Hospital in Lausanne, Switzerland (CHUV). We detected a total of 15 somatic *MAGE* coding region mutations in these cell lines, with at least one mutation in each of the five genes examined ([Table 1](#pone-0012773-t001){ref-type="table"}). Two other genes were also sequenced in these samples, *PRAME*, on chromosome 22 and *DDX53* on the X-chromosome, and served as negative controls as no mutations were found. As a positive control, the expected mutation frequencies of the major cancer genes *TP53* and *BRAF* were found in these cell lines ([Table S1](#pone.0012773.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0012773.t001

###### Somatic mutations identified in MAGE genes in the discovery set.

![](pone.0012773.t001){#pone-0012773-t001-1}

  Gene       Sample name     Amino acid   Codon change   TP53 status   BRAF status
  -------- ---------------- ------------ -------------- ------------- --------------
  MAGEA1      LAU-Me190         S33F        TCC\>TTC         WT           V600E
  MAGEA1      LAU-Me190        L129L        CTG\>CTA         WT           V600E
  MAGEA4      LAU-Me190         E34K        GAG\>AAG         WT           V600E
  MAGEC1      LAU-Me190        E877K        GAG\>AAG         WT           V600E
  MAGEC1      LAU-Me190        F144F        TTC\>TTT         WT           V600E
  MAGEC1      LAU-Me243        P756S        CCC\>TCC         WT             WT
  MAGEC1      LAU-Me200        G769R        GGG\>AGG        S241F           WT
  MAGEC2      LAU-Me275        S110N        AGC\>AAC         WT           V600E
  MAGEC2      LAU-Me243        R271R        AGG\>AGA         WT             WT
  MAGEC2      LAU-Me300        S111L        TCA\>TTA         WT           V600E
  MAGEC2    LAU-Me280.R.LN     P295L        CCA\>CTA        P278S      G593S; L597R
  MAGEC2      LAU-Me261         S51F        TCC\>TTC        S241F           WT
  MAGEE1      LAU-Me290        P324S        CCT\>TCT         WT             WT
  MAGEE1      LAU-T441A        P568L        CCC\>CTC         WT             WT
  MAGEE1      LAU-Me281        T330T        ACC\>ACG         WT           V600E

Overall, cell lines from 10 of the 27 patients exhibited *MAGE* mutations (37%). From five of the patients where MAGE mutations were found, fresh tumor tissue was also available. In four of these we were also able to identify the mutation found in the cell line in the fresh tissue. The exception was the tumor matching LAU-Me190 cells (five different mutations were found in the latter). One explanation for this could be tumor heterogeneity, which would render mutations present in small subset of cells undetectable by the sequencing technology used. To investigate this possibility, we selected one mutation, S33F in MAGEA1, for further study. We amplified the mutated region from the tumor tissue and cloned the amplification products into a plasmid and sequenced the clones. Two of 15 clones were found to contain the mutation. Thus for this mutation we were able to confirm the mutation in the original tissue in a subset of alleles.

Two of the mutations detected occurred in cell lines from patients for which additional autologous melanoma lines established from separate metastases were available. In one case, the lines (LAU-Me275 and LAU-T50B) were established twelve years apart and in the second (cell lines LAU-Me261 and LAU-T42B), the lines were established three years apart. We tested these additional lines for the presence of the mutations. In both cases, the mutations were found in the paired asynchronous cell lines.

Based on our finding of *MAGE* mutations in the melanoma cell line samples, a Validation Screen was undertaken in which we sequenced the same *MAGE* genes in 111 fresh tumor samples collected from 86 melanoma patients who had undergone surgical intervention at the Melanoma Clinic at Austin Health, Melbourne, Australia ([Table 2](#pone-0012773-t002){ref-type="table"}). In addition, we sequenced the same genes in 33 samples from ovarian tumors collected at Roswell Park Cancer Center, Buffalo, New York. We identified additional somatic coding region mutations for each of the genes in the melanoma samples. Overall, 32% of the melanoma patients had a mutation in at least one of the genes sequenced. The frequencies of patients with missense or nonsense mutations for the individual genes were 5.8%, 11.6%, 15.1% and 7.0% and 7.0% for *MAGEA1*, *MAGEA4*, *MAGEC1*, *MAGEC2* and *MAGEE1* respectively. More than one sample was available from six of the patients. In all cases where a *MAGE* mutation was found in one sample, it was also found to be present in the other samples from the same patient. We observed coding region mutation frequencies of 47.8% and 20.4% respectively for *BRAF* and *TP53* in the samples in the Validation Screen ([Table S2](#pone.0012773.s003){ref-type="supplementary-material"}). These frequencies are both consistent with those reported by others for these genes in melanoma arguing that our findings are representative. In contrast to the melanoma samples, no *MAGE* mutations were identified in any of the ovarian samples sequenced although a mutation frequency of 31% was found for *TP53* ([Table S4](#pone.0012773.s005){ref-type="supplementary-material"}). This frequency is consistent with the findings of others [@pone.0012773-Singer1] suggesting that the samples were sufficiently enriched for tumor derived cells to permit the detection of *MAGE* mutations were they to be present. The apparent lack of mutations in the ovarian samples studied points to a distinct tumorigenic pathway for the ovarian tumors and melanoma where MAGE genes may play different roles.

10.1371/journal.pone.0012773.t002

###### Somatic mutations identified in MAGE genes in the validation set.

![](pone.0012773.t002){#pone-0012773-t002-2}

  Gene      Sample name   Amino acid   Codon change        TP53 status        BRAF status
  -------- ------------- ------------ -------------- ----------------------- -------------
  MAGEA1      04-007        S296P        TCC\>CCC              WT                V600E
  MAGEA1       7552         L271F        CTC\>TTC              WT                V600E
  MAGEA1       4198         E217K        GAG\>AAG     R110C, Q100stop, P36L       NA
  MAGEA1       6227         D258A        GAT\>GCT         FS at H179\*            WT
  MAGEA1       6613         R236K        AGG\>AAG             R181P               WT
  MAGEA4       6541         G316R        GGA\>AGA              WT                V600E
  MAGEA4       7889          S99L        TCG\>TTG             R282P               WT
  MAGEA4       4198         E138K        GAG\>AAG     R110C, Q100stop, P36L       NA
  MAGEA4       4198         P149S        CCT\>TCT     R110C, Q100stop, P36L       NA
  MAGEA4       6985         E224K        GAG\>AAG              WT                 WT
  MAGEA4      02-105        P267S        CCT\>TCT              WT                 WT
  MAGEA4       7194         E242K        GAG\>AAG           R196stop              WT
  MAGEA4      03-043        R269C        CGC\>TGC              WT                 WT
  MAGEA4       5668         I222I        ATC\>ATT              WT                 WT
  MAGEA4       2112          E21E        GAG\>GAA              WT                V600E
  MAGEA4       5558          P45S        CCT\>TCT             S241F               WT
  MAGEC1      07-223        F904F        TTC\>TTT              WT                V600E
  MAGEC1      04-007         P26L        CCT\>CTT              WT                V600E
  MAGEC1      04-007         L35F        CTC\>TTC              WT                V600E
  MAGEC1       7889         E991K        GAG\>AAG             R282P               WT
  MAGEC1       4198          E59E        GAG\>GAA     R110C, Q100stop, P36L       NA
  MAGEC1       4198          D62N        GAC\>AAC     R110C, Q100stop, P36L       NA
  MAGEC1       4198          P38S        CCC\>TCC     R110C, Q100stop, P36L       NA
  MAGEC1       6985          P83S        CCC\>TCC              WT                 WT
  MAGEC1       6985         S688F        TCC\>TTC              WT                 WT
  MAGEC1       6985         S863L        TCA\>TTA              WT                 WT
  MAGEC1       6458         K1104K       AAG\>AAA             R248W               WT
  MAGEC1       7151         P119S        CCT\>TCT              WT                V600E
  MAGEC1       7194        Q664stop      CAG\>TAG           R196stop              WT
  MAGEC1       7194         E668E        GAG\>GAA           R196stop              WT
  MAGEC1       7194         P127L        CCT\>CTT           R196stop              WT
  MAGEC1       4066         F904F        TTC\>TTT              WT                V600E
  MAGEC1      02-024        L705L        CTG\>TTG           R213stop              WT
  MAGEC1       6795         G986E        GGG\>GAG              WT                 WT
  MAGEC1       4985         S964S        TCC\>TCA              WT                 WT
  MAGEC1       4985          S18S        TCC\>TCT              WT                 WT
  MAGEC1       4985         D687N        GAT\>AAT              WT                 WT
  MAGEC1       4062          P50S        CCT\>TCT              WT                V600K
  MAGEC1      03-063        S134S        TCC\>TCT              WT                G596R
  MAGEC2      07-223         P3S         CCC\>TCC              WT                V600E
  MAGEC2       4198         F151Y        TTC\>TAC     R110C, Q100stop, P36L       NA
  MAGEC2       4198          E36E        GAG\>GAA     R110C, Q100stop, P36L       NA
  MAGEC2       6985          S58F        TCC\>TTC              WT                 WT
  MAGEC2       7516         F265F        TTC\>TTT             R337S               WT
  MAGEC2       7259         D335N        GAT\>AAT              WT                 WT
  MAGEC2      02-102         P84P        CCC\>CCT              WT                V600E
  MAGEE1       6541         D446C       GAT\>TGT\*             WT                V600E
  MAGEE1       4198         R711K        AGG\>AAG     R110C, Q100stop, P36L       NA
  MAGEE1       6985         S319S        TCC\>TCT              WT                 WT
  MAGEE1      03-091        A717V        GCT\>GTT              WT                G469E
  MAGEE1      08-249E       A859A        GCC\>GCT              WT                V600K
  MAGEE1       8022          S67F        TCC\>TTC              WT                V600E
  MAGEE1       4985         E692D        GAA\>GAT              WT                 WT
  MAGEE1       4985         E693K        GAA\>AAA              WT                 WT

In addition to generating new mutation data, we also combed the publically available databases and found a small number of additional mutations in lung tumors, glioblastoma, breast tumors and melanoma in *MAGE* genes [@pone.0012773-Wood1], [@pone.0012773-Parsons1], [@pone.0012773-Jones1], [@pone.0012773-COSMIC1] ([Table 3](#pone-0012773-t003){ref-type="table"}). On the other hand, some tumor types known to express CT-X genes, such as colon, bladder and ovarian (as confirmed here), have no recorded mutations to date.

10.1371/journal.pone.0012773.t003

###### Somatic mutations identified in MAGE genes in genome wide surveys.

![](pone.0012773.t003){#pone-0012773-t003-3}

  Gene           Sample name (tumor type)        Amino acid   Codon change                   TP53 status                   BRAF status          Reference
  --------- ----------------------------------- ------------ -------------- --------------------------------------------- ------------- --------------------------
  MAGEA1     HCC1008 (breast cancer cell line)     K278T        AAA\>ACA                        D281H                          WT         [@pone.0012773-Wood1]
  MAGEA1        NCI-H1770 (NSCLC cell line)         A63P        GCC\>CCC                        R248W                          WT        [@pone.0012773-COSMIC1]
  MAGEA4     HCC1008 (breast cancer cell line)     G153D        GGC\>GAC                        D281H                          WT         [@pone.0012773-Wood1]
  MAGEA4              Br27P (glioma)               E221K        GAA\>AAA                   c.617delT (fs)                     T310I      [@pone.0012773-Parsons1]
  MAGEB6B       NCI-H2087 (NSCLC cell line)        G71\>F       GGT\>TTT                        V157F                         L597V      [@pone.0012773-COSMIC1]
  MAGEB10             Br09PT (glioma)               D55Y        GAT\>TAT                        W53X                           WT        [@pone.0012773-Parsons1]
  MAGEB10       LB647-SCLC (SCLC cell line)        Q148K        CAG\>AAG     p.E294fs[\*](#nt101){ref-type="table-fn"}51       WT        [@pone.0012773-COSMIC1]
  MAGEB16       NCI-H2009 (NSCLC cell line)        T302R        ACA\>AGA                        R273L                          WT        [@pone.0012773-COSMIC1]
  MAGEB16       LB647-SCLC (SCLC cell line)        A279T        GCT\>ACT     p.E294fs[\*](#nt101){ref-type="table-fn"}51       WT        [@pone.0012773-COSMIC1]
  MAGEB16    HCC2218 (breast cancer cell line)     L323L        CTG\>CTT                        R283C                          WT         [@pone.0012773-Wood1]
  MAGEC1              Br02X (glioma)               I1001F       ATT\>TTT                         WT                            WT        [@pone.0012773-Parsons1]
  MAGEC2     HCC1954 (breast cancer cell line)      G6C         GGC\>TGC                        Y163C                          WT         [@pone.0012773-Wood1]
  MAGEC3       MZ7-mel (melanoma cell line)         D50N        GAC\>AAC                         WT                           V600E      [@pone.0012773-COSMIC1]
  MAGEC3       CP66-MEL (melanoma cell line)       L551F        CTT\>TTT                         WT                            WT        [@pone.0012773-COSMIC1]
  MAGED2     Hs 578T (breast cancer cell line)     K458Q        AAG\>CAG                        V157F                          WT        [@pone.0012773-COSMIC1]
  MAGEE1     HCC2713 (breast cancer cell line)     Y640F        TAC\>TTC                   c.723delC (fs)                      NA        [@pone.0012773-COSMIC1]
  MAGEE1       CP66-MEL (melanoma cell line)       R934K        AGG\>AAG                         WT                            WT        [@pone.0012773-COSMIC1]
  MAGEE1     HCC1008 (breast cancer cell line)     T664N        ACC\>AAC                        D281H                          WT         [@pone.0012773-Wood1]
  MAGEE1          Pa14C (pancreas tumor)           V649V        GTG\>GTT                         WT                            WT         [@pone.0012773-Jones1]
  MAGEH1              Br23X (glioma)                A13A        GCG\>GCA                         WT                            WT        [@pone.0012773-Parsons1]
  MAGEH1        NCI-H2087 (NSCLC cell line)        F100F        TTC\>TTT                        V157F                         L597V      [@pone.0012773-COSMIC1]

\*Two consecutive changes.

The recent sequencing of a melanoma genome has revealed a mutation spectrum reflective of the mutagenic impact of ultraviolet light [@pone.0012773-Pleasance1]. This pattern can be clearly observed in this study in that C\>T - G\>A alterations represent almost 89% of the *MAGE* mutations found ([Table S5](#pone.0012773.s006){ref-type="supplementary-material"}), with over 90% of these occurring at dipyrimidine sites. This UV mutation signature pattern was also observed for *TP53* in the melanoma samples analyzed here. It was not, however, observed in the *MAGE* mutations found in other tumor types.

Overall, the non-synonymous to synonymous ratio of the *MAGE* mutations was found to be 2.45∶1. This is not different from the ratio that would be expected to occur by chance. However, this low non-synonymous:synonymous ratio is largely due to a very high proportion of synonymous mutations in *MAGEC1* and *MAGEC2* (14 of 20). *MAGEA1*, *MAGEA4*, and *MAGEE1* have non-synonymous to synonymous ratios of 6∶1, 5∶1 and 2.66∶1 respectively. Moreover, all the mutations in the two *MAGEA* genes reported in the databases are non-synonymous ([Table 1](#pone-0012773-t001){ref-type="table"}). Thus, *MAGEA* mutations might be drivers of tumorigenesis, as has previously been postulated for *MAGEE1*. Due to their distribution throughout the genes studied ([Figure 1](#pone-0012773-g001){ref-type="fig"}), we speculate that the *MAGE* mutations we have identified are more likely to be inactivating than activating. Consistent with this, for the *MAGEA* genes where the NS:S ratio is suggestive of their being drivers, there is evidence that both play tumor suppressive roles. *MAGEA1* expression was shown to correlate with good prognosis in neuroblastoma [@pone.0012773-Grau1] and *MAGEA4* expression was shown to promote tumor cell death and sensitize lung malignancies to apoptotic stimuli, such as chemotherapeutic agents [@pone.0012773-Peikert1]. MAGEA4 was also shown to interact with gankyrin and to suppress its oncogenic activity [@pone.0012773-Nagao1]. It is thus possible, that the inactivation of *MAGEA1* and *MAGEA4*, which are generally expressed in coordination with other CT-X genes such as *MAGEA2* and *MAGEA3* for which there is evidence for oncogenic function, might enhance the overall tumorigenicity of coordinated CT-X expression leading to a net positive contribution to tumor progression.

![Distribution of mutations in the *MAGE* genes analyzed in this study.\
In red are the non-synonymous and in black the synonymous mutations. Asterisks indicate mutations that were identified in other studies.](pone.0012773.g001){#pone-0012773-g001}

Recently the X-ray structure of the MAGE homology domain of *MAGEA4* (PDB ID 2WA0) was determined. This permitted a more detailed analysis of the mutations that fall within this domain in the various family members, as described in [Supplementary Methods S1](#pone.0012773.s001){ref-type="supplementary-material"}. We found that the mutations found in this region involve residues that have a higher solvent exposure and a lower FoldX score [@pone.0012773-Guerois1] than average, implying that they do not play an important role in the structural integrity of the protein but might serve for interactions with other molecules ([Supplementary Methods S1](#pone.0012773.s001){ref-type="supplementary-material"} and [Table S6](#pone.0012773.s007){ref-type="supplementary-material"}). Although it is unclear whether the MAGE homology domain is involved in binding interactions, this observation reinforces the possibility of the mutations resulting in discrete functional changes.

One other aspect of the MAGE gene mutations worthy of further investigation is their frequent occurrence in potential phosphorylation sites. As predicted by <http://scansite.mit.edu/>, these mutations could either abolish predicted existing sites or create new potential sites (A63P \[new site at S62\], K278T and S296P in MAGEA1; P45S, S99L, P149S and P267S in MAGEA4; P38S, P83S and S86L in MAGEC1; S51F, S58F, S110N, S111L, F151Y and P295L \[new sites at S293, Y296 and Y297\] in MAGEC2). Although at this stage we have no direct evidence that the MAGE proteins are phosphorylated, this observation does hint at potential functional consequence of many of the mutations.

Lastly, we considered the possibility that selective immune pressure that might underlie the *MAGE* mutations. In this context, six of the eight missense mutations identified in *MAGEA1* (residues 63, 236, 258, 271, 278, 296), the only one of the genes sequenced where extensive mapping of T cell epitopes has been performed, affect known epitopes \[26\]. Thus, the mutations might reduce antigenicity and serve as an alternate escape mechanism to loss of antigen or MHC expression. It remains to be determined, however, whether the mutated epitopes were involved in antigenicity in the patients where they were identified.

A notable facet of the *MAGE* mutations is their non-random distribution between patients. Thirty five of the fifty four *MAGE* mutations (64.8%) in our Validation and Discovery Screens are from samples that exhibit more than one mutation, often with multiple mutations in the same gene. For example, one sample in the Validation Screen, 4198, exhibited nine coding region mutations and another, 6985, six mutations. Even in the list of mutations identified in other studies, 41% are from samples where more than one *MAGE* mutation has been identified. These data suggest that a significant subset of the mutations might arise due to a DNA instability syndrome, either affecting the X-chromosome or the entire genome.

While our results do not as yet define the functional consequences of the MAGE gene mutations observed, they do demonstrate for the first time that this gene family is frequently mutated in melanoma. Therefore, our study argues for enhanced efforts to discern potential tumorigenic properties of these genes that serve as the platform for therapeutic cancer vaccines already in advanced clinical development.
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